Page 45 - 2021_07-Haematologica-web

Red cell transfusion and alloimmunization in SCD
87. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062- 1064.
88.Chonat S, Graciaa S, Shin HS, et al. Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease. Haematologica. 2020;105(12):2887- 2891.
89. Unnikrishnan A, Pelletier JPR, Bari S, et al. Anti-N and anti-Do(a) immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Transfusion. 2019;59(6):1907- 1910.
90. Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. Life-threatening delayed hyper- hemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015;55(10):2398-2403.
91. Mpinganzima C, Haaland A, Holm AGV, Thein SL, Tjønnfjord GE, Iversen PO. Two consecutive episodes of severe delayed hemolytic transfusion reaction in a sickle cell disease patient. Case Rep Hematol. 2020;2020:2765012.
92. Vlachaki E, Gavriilaki E, Kafantari K, et al. Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement inhibi- tion. Hemoglobin. 2018;42(5-6):339-341.
93. Sivapalaratnam S, Linpower L, Sirigireddy B, et al. Treatment of post-transfusion hyper- haemolysis syndrome in sickle cell disease with the anti-IL6R humanised monoclonal antibody tocilizumab. Br J Haematol. 2019;186(6):e212-e214.
94. Lee LE, Beeler BW, Graham BC, Cap AP, Win N, Chen F. Posttransfusion hyperhe- molysis is arrested by targeting macrophage
activation with novel use of tocilizumab.
Transfusion. 2020;60(1):30-35.
95. Hair PS, Heck TP, Carr DT, et al. Delayed
hemolytic transfusion reaction in a patient with sickle cell disease and the role of the classical complement pathway: a case report. J Hematol. 2021;10(1):18-21.
96. Wang CY, Babitt JL. Liver iron sensing and body iron homeostasis. Blood. 2019;133(1): 18-29.
97. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in trans- fused patients with SCD or beta tha- lassemia. Am J Hematol. 2005;80(1):70-74.
98. Meloni A, Puliyel M, Pepe A, Berdoukas V, Coates TD, Wood JC. Cardiac iron overload in sickle-cell disease. Am J Hematol. 2014;89 (7):678-683.
99. Perronne V, Roberts-Harewood M, Bachir D, et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J. 2002;3(1):56-60.
100.Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81(11):858-863.
101. Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld EJ. Liver MRI is more precise than liver biopsy for assessing total body iron bal- ance: a comparison of MRI relaxometry with simulated liver biopsy results. Magn Reson Imaging. 2015;33(6):761-767.
102. Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol. 2017;177(5):703-716.
103.Maggio A, Kattamis A, Felisi M, et al. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-depen- dent haemoglobinopathies (DEEP-2): a mul- ticentre, randomised, open-label, non-inferi- ority, phase 3 trial. Lancet Haematol. 2020;7(6):e469-e478.
104. Sridharan K, Sivaramakrishnan G. Efficacy and safety of iron chelators in thalassemia
and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert Rev Clin Pharmacol. 2018;11(6):641-650.
105.Fasano RM, Leong T, Kaushal M, Sagiv E, Luban NL, Meier ER. Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concur- rently with iron chelation therapy in reduc- ing iron overload in chronically transfused sickle cell anemia patients. Transfusion. 2016;56(7):1707-1715.
106. Piel FB, Patil AP, Howes RE, et al. Global epi- demiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-151.
107. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early child- hood mortality. Am J Prev Med. 2011;41(6 Suppl 4):S398-405.
108. World Health Organization. Global status report on blood safety and availability 2016. Geneva: World Health Organization. Accessed in April, 2017.
109.Dzik WS, Kyeyune D, Otekat G, et al. Transfusion medicine in sub-Saharan Africa: conference summary. Transfus Med Rev. 2015;29(3):195-204.
110. Waiswa MK, Moses A, Seremba E, Ddungu H, Hume HA. Acute transfusion reactions at a national referral hospital in Uganda: a prospective study. Transfusion. 2014;54(11): 2804-2810.
111. Jayaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I. The risk of transfusion-transmit- ted infections in sub-Saharan Africa. Transfusion. 2010;50(2):433-442.
112.
Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmu- nization in transfused patients with sickle cell disease in sub-Saharan Africa; a system- atic review and meta-analysis. Transfus Med Rev. 2019;33(3):162-169.
haematologica | 2021; 106(7)
1815